Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E T Creagan

Showing results (21-30 of 112) with videos related to

Pageof 12
Sort By:
American Journal of Clinical Oncology|April 1, 1989
A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanomaE T Creagan, J N Ingle, A J Schutt, et al.
Cancer|December 15, 1988
A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanomaE T Creagan, C L Loprinzi, D L Ahmann, et al.
Cancer|August 11, 1975
Six families prone to ovarian cancerJ F Fraumeni, G W Grundy, E T Creagan, et al.
American Journal of Surgery|October 1, 1979
Radiation therapy for malignant melanoma of the head and neckE T Creagan, J E Woods, R E Cupps, et al.
American Journal of Clinical Oncology|June 1, 1993
A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanomaE T Creagan, D J Schaid, L C Hartmann, et al.
Cancer|April 1, 1982
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanomaE T Creagan, J N Ingle, D L Ahmann, et al.
Oncology|January 1, 1977
A clinical trial adriamycin (NSC 123127) in advanced sarcomasE T Creagan, R G Hahn, D L Ahmann, et al.
Medical and Pediatric Oncology|January 1, 1986
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanomaE T Creagan, A J Schutt, H J Long, et al.
American Journal of Clinical Oncology|April 1, 1991
A technetium-labeled monoclonal antibody for imaging metastatic melanomaS Frytak, E T Creagan, M L Brown, et al.
American Journal of Clinical Oncology|June 1, 1992
Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanomaE R Feldman, E T Creagan, D J Schaid, et al.
Pageof 12

Showing results (21-30 of 112) with videos related to

Sort By:
Pageof 12
American Journal of Clinical Oncology|April 1, 1989
A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanomaE T Creagan, J N Ingle, A J Schutt, et al.
Cancer|December 15, 1988
A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanomaE T Creagan, C L Loprinzi, D L Ahmann, et al.
Cancer|August 11, 1975
Six families prone to ovarian cancerJ F Fraumeni, G W Grundy, E T Creagan, et al.
American Journal of Surgery|October 1, 1979
Radiation therapy for malignant melanoma of the head and neckE T Creagan, J E Woods, R E Cupps, et al.
American Journal of Clinical Oncology|June 1, 1993
A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanomaE T Creagan, D J Schaid, L C Hartmann, et al.
Cancer|April 1, 1982
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanomaE T Creagan, J N Ingle, D L Ahmann, et al.
Oncology|January 1, 1977
A clinical trial adriamycin (NSC 123127) in advanced sarcomasE T Creagan, R G Hahn, D L Ahmann, et al.
Medical and Pediatric Oncology|January 1, 1986
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanomaE T Creagan, A J Schutt, H J Long, et al.
American Journal of Clinical Oncology|April 1, 1991
A technetium-labeled monoclonal antibody for imaging metastatic melanomaS Frytak, E T Creagan, M L Brown, et al.
American Journal of Clinical Oncology|June 1, 1992
Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanomaE R Feldman, E T Creagan, D J Schaid, et al.
Pageof 12